Eur J Endocrinol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


DOI: 10.1530/eje.0.1320544
European Journal of Endocrinology, Vol 132, Issue 5, 544-545
Copyright © 1995 by European Society of Endocrinology
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hegedüs, L.
Right arrow Articles by Faber, J.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Hegedüs, L.
Right arrow Articles by Faber, J.

Calculation of the ideal dose of radioiodine for treatment of thyroid disease

Laszlo Hegedüs and Jens Faber

Radioactive iodine (131I) has been used for half a century and proved effective in treating hyperthyroidism. It is safe, cheap and relatively free from side effects. Iodine-131 is used in most cases of nodular toxic goitre and regarded as the treatment of choice for patients with Graves' disease who do not remit following a course of antithyroid drugs (1, 2). Although large surveys among European (3) and American (4) thyroidologists have disclosed some differences in attitude, this treatment is increasingly used. In fact, many thyroidologists have come to the conclusion that antithyroid drugs aiming at inducing remission of the hyperthyroidism should be reserved for young patients and those with normal or only slightly increased thyroid size. In Denmark this would limit the use of antithyroid drugs—for the purpose of inducing remission—to not more than 25% of the patients with hyperthyroidism (5, 6).

Recently, renewed interest in the treatment of







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1995 European Society of Endocrinology.